Skip to main content

Advertisement

Table 3 Burden of care and hospitalization costs in the matched patients

From: Cost-effectiveness of activated protein C in real-life clinical practice

  All patients (n = 840) Survivors (n = 471) Nonsurvivors (n = 369)
  Pre-license Post-license Pre-Post license difference (95% CI) Pre-license Post-license Pre-Post license difference (95% CI) Pre-license Post-license Pre-Post license difference (95% CI)
Omega score 373 427* 54 (9.12 to 98.03) 380 433 53 (-10 to 112) 364 418 54 (-13 to 121)
Reference cost index 2,430 2,862* 432 (187 to 662) 2,254 2,667* 413 (96 to 722) 2,648 3,121* 473 (9 to 936)
ICU stay (day) 21.3 24.4* 3.1 (0.32 to 5.92) 23.8 26.7 2.9 (-0.90 to 6.57) 18.2 21.3 3.1 (-0.89 to 7.25)
Hospital stay (day) 37.9 40.4 2.5 (-1.79 to 6.84) 49.2 51.1 1.9 (-4.41 to 8.37) 24.6 27.5 2.9 (-2.02 to 7.95)
Costs -rhAPC (€) 36,717 41,144 4,427 (-85 to 8,991) 35,575 39,172 3,597 (-1,737 to 8,680) 38,095 43,729 5,634 (-2,005 to 13,380)
Total costs (€) 36,717 47,870* 11,153 (6,601 to 15,709) 35,575 46,752* 11,177 (5,863 to 16,313) 38,095 49,336* 11,241 (3,433 to 19,084)
  1. Values are expressed means and 95% confidence interval (CI) on the means. *P < 0.05 pre-license versus post-license. P < 0.05 post-license survivors versus nonsurvivors. ICU, intensive care unit; rhAPC, recombinant human activated protein C; -rhAPC, without rhAPC acquisition costs.